Compare Amgen, Inc. (AMGN) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Main Street Capital Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Main Street Capital Corporation trades at $52.98 (market cap $4.91B). The key difference: Amgen, Inc. is far larger — about 39.9× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.29%). Which is the better fit depends on your goals.
| AMGN | MAIN | |
|---|---|---|
Market Cap | $196.12B | $4.91B |
Sector | Health | Financials |
52-Week High | $388.16 | $67.54 |
52-Week Low | $271.18 | $49.63 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 8.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Main Street Capital (MAIN) trades at $52.84, up 2.26% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with an 81.08% net margin and 14.37% ROE, though recent quarters show inconsistent earnings performance with two misses and one beat. Revenue declined slightly from $601M in 2024 to $592M in 2025, with further contraction projected for 2026. The stock pays consistent dividends, with recent payments ranging from $0.26 to $0.30 per share.
MAIN presents a cautious outlook with analysts showing 78.57% hold ratings despite a $57.75 consensus price target suggesting 9.3% upside. The bearish technical trend and projected revenue decline to $526M in 2026 create headwinds, while strong profitability metrics and dividend consistency provide support. Investors face balancing attractive valuation (P/E 11.12) against earnings volatility and negative operating cash flow of -$45.71M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
